OverviewSuggest Edit

Catalent Pharma Solutions is a company providing integrated services, drug delivery technologies, and manufacturing solutions for drugs, protein, cell, and gene therapy biologics, and consumer health products. It operates through Softgel and Oral Technologies, Biologics, and Oral and Specialty Delivery segments. The company offers formulation, development, and manufacturing of oral solid dose forms; biologic cell-line, cell therapy, and viral vector gene therapy; drugs and biologics in clinical trials. Catalent serves the pharmaceuticals, biologics, and consumer health products development markets.
TypePublic
Founded2007
HQFranklin Township, NJ, US
Websitecatalent.com
Employee Ratings3.5
Overall CultureA+

Latest Updates

Employees (est.) (Jun 2020)13,900(+14%)
Job Openings1,146
Revenue (FY, 2020)$3.1 B(+23%)
Share Price (Jun 2021)$108.6(-1%)
Cybersecurity ratingCMore

Key People/Management at Catalent

John Chiminski

John Chiminski

Chair & Chief Executive Officer
Alessandro Maselli

Alessandro Maselli

President & Chief Operating Officer
Kristen Devito

Kristen Devito

Vice President, Operations, North America
Wetteny Joseph

Wetteny Joseph

Senior Vice President & Chief Financial Officer
Mike Riley

Mike Riley

Region President, Biologics, North America
Mario Gargiulo

Mario Gargiulo

Region President, Biologics, Europe
Show more

Catalent Office Locations

Catalent has offices in Franklin Township, Baltimore, Bloomington, Emeryville and in 37 other locations
Franklin Township, NJ, US (HQ)
14 School House Rd, Somerset
Baltimore, MD, US
801 W Baltimore St Suite 302
Bloomington, IN, US
1300 S Patterson Dr
Emeryville, CA, US
5959 Horton St #400
Gaithersburg, MD, US
20 Firstfield Rd
Halethorpe, MD, US
5521 Research Park Dr
Show all (44)

Catalent Financials and Metrics

Catalent Revenue

Embed Graph
View revenue for all periods
Catalent's revenue was reported to be $3.09 b in FY, 2020 which is a 22.9% increase from the previous period.
USD

Revenue (Q2, 2021)

910.8m

Gross profit (Q2, 2021)

298.2m

Gross profit margin (Q2, 2021), %

32.7%

Net income (Q2, 2021)

88.4m

EBIT (Q2, 2021)

126.6m

Market capitalization (18-Jun-2021)

18.5b

Closing stock price (18-Jun-2021)

108.6

Cash (31-Dec-2020)

833.1m

EV

20.7b
Catalent's current market capitalization is $18.5 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

2.5b2.5b3.1b

Revenue growth, %

19%2%23%

Cost of goods sold

1.7b1.7b2.1b

Gross profit

752.6m805.1m983.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

551.8m623.0m617.5m664.7m721.4m760.6m845.7m910.8m

Cost of goods sold

403.3m421.6m418.8m487.0m489.2m521.8m596.8m612.6m

Gross profit

148.5m201.4m198.7m177.7m232.2m238.8m248.9m298.2m

Gross profit Margin, %

27%32%32%27%32%31%29%33%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

410.2m345.4m953.2m

Accounts Receivable

555.8m716.4m838.1m

Inventories

209.1m257.2m323.8m

Current Assets

1.2b1.4b2.3b
Quarterly
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

83.6m137.4m220.7m

Depreciation and Amortization

190.1m228.6m253.7m

Inventories

(1.8m)(34.0m)(76.4m)

Accounts Payable

32.3m36.2m72.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(14.4m)34.6m66.3m100.0k45.6m66.5m82.4m170.8m

Depreciation and Amortization

52.9m107.5m173.9m60.6m122.5m253.6m69.1m140.1m

Inventories

(21.0m)(26.0m)(43.1m)200.0k(11.6m)(54.7m)(65.4m)(140.3m)

Accounts Payable

(18.3m)(11.3m)5.9m(47.3m)(13.3m)29.9m6.6m13.4m
USDFY, 2018

EV/EBIT

29.1 x

EV/CFO

21.1 x

Revenue/Employee

230.2k

Debt/Equity

2.5 x

Debt/Assets

0.6 x

Financial Leverage

4.2 x

P/E Ratio

66.5
Show all financial metrics

Catalent Operating Metrics

Catalent's Backlog was reported to be $2.3b in FY, 2020. Catalent's Customers was reported to be 1 k in FY, 2020.
FY, 2017FY, 2018FY, 2019FY, 2020

Backlog

$1.05 b$1.11 b$1.35 b$2.28 b

Countries

80808085

Customers

1 k1 k1 k1 k

Products

7 k7 k7 k7 k
Show all operating metrics

Catalent Acquisitions / Subsidiaries

Company NameDateDeal Size
Bone TherapeuticsOctober 29, 2020
MaSTherCellFebruary 03, 2020$315 m
Paragon BioservicesApril 15, 2019$1.2 b
Juniper PharmaceuticalsJuly 02, 2018$128 m
Cook Pharmica LLCOctober 24, 2017
Pharmatek LaboratoriesSeptember 13, 2016
Micron TechnologiesNovember 13, 2014
Redwood BioscienceOctober 01, 2014
Accucaps Industries
Catalent Anagni S.r.l.
Show more

Catalent Revenue Breakdown

Embed Graph

Catalent revenue breakdown by business segment: 32.9% from Biologics, 21.8% from Oral and Specialty Delivery, 11.1% from Clinical Supply Services and 34.2% from Softgel and Oral Technologies

Catalent revenue breakdown by geographic segment: 57.4% from United States, 30.8% from Europe and 11.8% from Other

Catalent Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Catalent Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Catalent Online and Social Media Presence

Embed Graph

Catalent Company Culture

  • Overall Culture

    A+

    80/100

  • CEO Rating

    A+

    77/100

  • Compensation

    A+

    81/100

Learn more on Comparably

Catalent News and Updates

North American Healthcare Contract Development and Manufacturing Organization Market Report 2021 Featuring AbbVie, Baxter International, Catalent, Pfizer, Thermo Fisher Scientific & Jabil

Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "North American Healthcare CDMO Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The North American healthcare CDMO market is estimated to grow significantly during the forecast period.

Catalent, Longstanding TOMI Pharmaceutical Partner, Expands SteraMist Disinfection Across Multiple U.S. Locations

FREDERICK, Md., June 07, 2021 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, announced the…

Catalent, the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.

Catalent, the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has made an investment to expand capabilities at its clinical supply…

Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has completed the expansion of two new suites at its biologics drug substance develop…

ABEC CSR® Single-Use Fermenters to Support Catalent Cell & Gene Therapy Manufacturing Expansion

ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that it has supplied two 50L CSR single-use fermenters to Catalent Cell & Gene Therapy.

Catalent to nearly double U.S. production of Moderna’s COVID-19 vaccine

Contract manufacturer Catalent Inc has signed an agreement that will nearly double the U.S. production of Moderna Inc's COVID-19 vaccine, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Show more

Catalent Blogs

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Catalent today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).

Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms

Summary: Experts will share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications.

Catalent Career Fair: Boston, Massachusetts

We’re Hiring! Catalent has a new site in Boston, MA is growing and looking to add talent like you! We look forward to meeting you Monday, June 28th, 2021.

Bloomington, IN 360° Virtual Tour

In this 360 Virtual Tour of Catalent Biologics’ Bloomington, Indiana main campus, explore our award-winning facility and its integrated development, drug substance, drug product and secondary packaging operations.

Oral Dose – Anagni, Italy 360° Virtual Tour

Catalent’s Anagni facility is a world-class, late-stage and commercial product launch site offering primary and secondary packaging of oral solids. The site provides high-speed and high-capacity blister packaging, blister cartoning and bottle cartoning lines for stand-alone and integrated packaging…

CivicaScript, the Newly Named Civica Initiative to Serve Patients in Retail Markets, Announces a New Health Plan Partner, a New President, and a New Drug Manufacturing Partner

Catalent will develop a range of CivicaScript-owned generic drug Abbreviated New Drug Applications (ANDAs).
Show more

Catalent Frequently Asked Questions

  • When was Catalent founded?

    Catalent was founded in 2007.

  • Who are Catalent key executives?

    Catalent's key executives are John Chiminski, Alessandro Maselli and Kristen Devito.

  • How many employees does Catalent have?

    Catalent has 13,900 employees.

  • What is Catalent revenue?

    Latest Catalent annual revenue is $3.1 b.

  • What is Catalent revenue per employee?

    Latest Catalent revenue per employee is $222.6 k.

  • Who are Catalent competitors?

    Competitors of Catalent include Vetter Pharma, Eurofins and WuXi Biologics.

  • Where is Catalent headquarters?

    Catalent headquarters is located at 14 School House Rd, Somerset, Franklin Township.

  • Where are Catalent offices?

    Catalent has offices in Franklin Township, Baltimore, Bloomington, Emeryville and in 37 other locations.

  • How many offices does Catalent have?

    Catalent has 44 offices.